These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17970224)

  • 1. High throughput crystallography of TB drug targets.
    Murillo AC; Li HY; Alber T; Baker EN; Berger JM; Cherney LT; Cherney MM; Cho YS; Eisenberg D; Garen CR; Goulding CW; Hung LW; Ioerger TR; Jacobs WR; James MN; Kim C; Krieger I; Lott JS; Sankaranarayanan R; Segelke BW; Terwilliger TC; Wang F; Wang S; Sacchettini JC
    Infect Disord Drug Targets; 2007 Jun; 7(2):127-39. PubMed ID: 17970224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R; Zahra NU; Azam SS
    Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing the structural coverage of tuberculosis drug targets.
    Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
    Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Expanding Diversity of Mycobacterium tuberculosis Drug Targets.
    Wellington S; Hung DT
    ACS Infect Dis; 2018 May; 4(5):696-714. PubMed ID: 29412643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered drug efflux under iron deprivation unveils abrogated MmpL3 driven mycolic acid transport and fluidity in mycobacteria.
    Pal R; Hameed S; Fatima Z
    Biometals; 2019 Feb; 32(1):49-63. PubMed ID: 30430296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
    Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
    Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics.
    Fang Z; van der Merwe RG; Warren RM; Schubert WD; Gey van Pittius NC
    Tuberculosis (Edinb); 2015 Mar; 95(2):131-6. PubMed ID: 25578513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel targets in M. tuberculosis: search for new drugs.
    Lamichhane G
    Trends Mol Med; 2011 Jan; 17(1):25-33. PubMed ID: 21071272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An
    Kumar S; Sahu P; Jena L
    Int J Mycobacteriol; 2019; 8(3):252-261. PubMed ID: 31512601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activity.
    Lin Y; Zhang H; Zhu N; Wang X; Han Y; Chen M; Jiang J; Si S
    Tuberculosis (Edinb); 2018 May; 110():79-85. PubMed ID: 29779778
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Taira J; Ito T; Nakatani H; Umei T; Baba H; Kawashima S; Maruoka T; Komatsu H; Sakamoto H; Aoki S
    Int J Mycobacteriol; 2017; 6(2):142-148. PubMed ID: 28559515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamins Based Novel Target Pathways/Molecules as Possible Emerging Drug Targets for the Management of Tuberculosis.
    Sharma A; Jain K; Flora SJS
    Med Chem; 2018; 14(3):212-224. PubMed ID: 29110620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
    Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
    J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery.
    Lou Z; Zhang X
    Protein Cell; 2010 May; 1(5):435-42. PubMed ID: 21203958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidation of marine fungi derived anthraquinones as mycobacterial mycolic acid synthesis inhibitors: an in silico approach.
    Sharma A; Islam MH; Fatima N; Upadhyay TK; Khan MKA; Dwivedi UN; Sharma R
    Mol Biol Rep; 2019 Apr; 46(2):1715-1725. PubMed ID: 30715689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tuberculosis structural genomics consortium: a structural genomics approach to drug discovery.
    Musa TL; Ioerger TR; Sacchettini JC
    Adv Protein Chem Struct Biol; 2009; 77():41-76. PubMed ID: 20663481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.